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Background/aim: The aim of this study was to determine the prevalence and associated factors of thrombocytopenia in human
immunodeficiency virus (HIV)-infected patients.
Materials and methods: A cross-sectional study was conducted in a tertiary care hospital in İzmir, Turkey. All HIV-infected patients
admitted to the Department of Infectious Diseases and Clinical Microbiology between 2006 and 2011 were recruited. Patients with
thrombocytopenia at any time point were defined as the case group and the remaining patients were defined as the control group.
Results: The frequency of thrombocytopenia was 35.8%. Thrombocytopenia was more frequent in patients with acquired immune
deficiency syndrome (AIDS) than in patients without AIDS (P < 0.05) and in antiretroviral-naive patients than in patients on
combination antiretroviral therapy (cART) or those who had ever used cART in the past (P < 0.05). Additionally, rates of tuberculosis
infection, prophylactic use of trimethoprim-sulfamethoxazole (TMP/SMX), and being anti-HCV seropositive at any time point were
higher in patients with thrombocytopenia than in the control group (P < 0.05), and the case group had lower CD4+ T lymphocytes at
first admission (P < 0.05).
Conclusion: The main finding was the clear association between thrombocytopenia and advanced and uncontrolled HIV infection.
Tuberculosis and HCV coinfections were also identified as associated factors for thrombocytopenia.
Key words: Thrombocytopenia, HIV, AIDS

1. Introduction
Hematologic abnormalities are one of the most frequent
complications of human immunodeficiency virus (HIV)
infection and a frequent cause of death in HIV-infected
patients (1–6). HIV infection of lymphocytes, monocytes,
and macrophages is thought to induce abnormalities in
cytokine production that in turn affect hematopoiesis.
In addition, infections, malignancies, and drug-induced
myelosuppression contribute to the development of
cytopenias in HIV-infected patients (2,7–9). Despite the
frequency of cytopenias tending to increase as the disease
progresses, thrombocytopenia (<150,000/µL) may occur
in all stages of HIV infection (10–17). Cytopenias play an
important role in HIV-related morbidity and have a major
impact on quality of life (2,7–9). Before the introduction of
combination antiretroviral therapy (cART), the prevalence
of thrombocytopenia associated with HIV infection ranged
from 5% to 30% (3,10,18–23). Thrombocytopenia was also
* Correspondence: drchh@hotmail.com

identified as a poor prognostic factor for progression of
HIV infection to acquired immune deficiency syndrome
(AIDS) and death (3,4). Prolonged survival of HIVinfected patients after the introduction of cART may also
cause new complications. Combination antiretroviral
therapy may itself lead to hematological toxicities (24).
Severe thrombocytopenia, which requires treatment and
bleeding diathesis, can be seen in HIV-infected patients on
cART (25).
A recently published study reported that the frequency
of thrombocytopenia varied among countries and that
the geographical distribution of thrombocytopenia
differed from that of neutropenia and anemia in HIVinfected patients (26). Studies regarding the frequency of
thrombocytopenia in HIV-infected patients in Turkey are
very limited (27). The primary aim of this study was to
determine the frequency of thrombocytopenia in HIVinfected patients followed in our clinic and the second
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purpose was to determine the factors associated with
thrombocytopenia.
2. Materials and methods
This cross-sectional study was conducted in the
Department of Infectious Diseases and Clinical
Microbiology of a tertiary care hospital. All HIVinfected patients admitting to the department between
January 2006 and December 2011 were consecutively
recruited for the study. In this population, the frequency
of thrombocytopenia was investigated. Patients with
thrombocytopenia at any time point were defined as the
case group and the remaining patients were defined as
the control group. Consequently, the case and the control
groups were compared regarding demographic (sex, age at
the time of diagnosis), clinical (duration of HIV infection,
duration of follow-up, clinical stage, treatment history,
and comorbid diseases, malignancies, and opportunistic
infections at any time point), and laboratory (plasma HIV1 RNA, CD4+ T lymphocyte count, complete blood count)
features. For the case group, duration and probable cause
of thrombocytopenia; presence of anemia, leukopenia,
and/or neutropenia; presence or history of bleeding; and
the interventions for the treatment of thrombocytopenia
were evaluated.
HIV infection was diagnosed in the presence of a
reactive screening test (ELISA) result confirmed by a
western blot analysis. Patients were staged according to
CDC recommendations (28). Platelet count of <150,000/
µL was considered as thrombocytopenia. Hemoglobin
levels of <13.0 g/dL in males, <12.0 g/dL in females, and
<11.0 g/dL in pregnant women were considered as anemia.
Leukocyte counts of <4000/µL and neutrophil counts of
<1500/µL were considered as leukopenia and neutropenia,
respectively. Duration of HIV infection was defined as the
time since first HIV diagnosis and the duration of followup was defined as the time between the first and the last
admissions. Acute and chronic thrombocytopenia were
defined as thrombocytopenia persisting <3 months and ≥3
months, respectively. Data were obtained by retrospective
scanning of patient files and computer records between 1
May and 30 June 2012.
Statistical analysis was performed using SPSS 15.0
(SPSS Inc., USA). Descriptive statistics (median, minimum
and maximum values, mean, standard deviation, count,
and percentage) were used to summarize the results.
Differences in normally distributed continuous variables
were analyzed using an independent samples t-test.
Comparisons of skewed data were analyzed using the
Mann–Whitney U test. The chi-square or Fisher’s exact
test was used to compare categorical variables between the
2 groups. P < 0.05 was considered as statistically significant
and the null hypothesis was rejected.
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3. Results
A total of 95 HIV-infected patients were evaluated. Total
duration of follow-up was 403 patient-years. At first
admission, the median CD4+ T lymphocyte count was
280 (range: 0–1380) cells/µL and the median plasma HIVRNA level was 41,250 (range: <20–5,730,000) copies/µL:.
Patient characteristics are shown in Table 1. Six (6.3%)
deaths were found. Causes of death were AIDS in 2
patients and non-Hodgkin lymphoma, lung cancer, rectal
squamous cell carcinoma, and liver cirrhosis in 1 patient
each. Thrombocytopenia was found in 5 of the 6 patients
who died.
Overall, thrombocytopenia was found in 35.8% (n =
34) of the patients. Prevalence decreased to 24.2% and to
10.5% if platelet count of less than 100,000/µL (23) and less
than 50,000/µL (10) was used to define thrombocytopenia,
respectively. The characteristics of these patients are
presented in Table 2. Possible causes of thrombocytopenia
were HIV/AIDS in 22 patients (64.7%), liver cirrhosis in
3 (8.8%) patients, and didanosine usage, acute hepatitis C
and chemotherapy in 1 (2.9%) patient each.
Frequency of thrombocytopenia was similar in male
(39.5%) and female (21.1%) patients (P > 0.05). There was
no significant difference between the case and the control
group regarding median age (37 and 38 years, respectively).
When compared, thrombocytopenia was more frequent in
patients in AIDS stages than patients not in AIDS stages of
HIV infection (P < 0.05) and in cART-naive patients than
in patients on cART or who had ever used cART in the past
(P < 0.05). Additionally, rates of tuberculosis, prophylactic
use of trimethoprim-sulfamethoxazole (TMP/SMX), and
being anti-HCV seropositive at any time point were higher
in the case group than the control group (P < 0.05). The
case group also had a lower CD4+ T lymphocyte count
at first admission (P < 0.05). No statistically significant
differences were detected between the 2 groups regarding
other characteristics. Comparisons of the 2 groups are
shown in Tables 3 and 4. In addition to its association with
thrombocytopenia, patients with tuberculosis also had a
significantly lower CD4+ T lymphocyte count (median:
73.0, range: 1–686 cells/µL) than patients who did not
have tuberculosis (median: 324, range: 0–1380 cells/µL) (P
< 0.05).
4. Discussion
This study showed that thrombocytopenia was an
important issue to consider in our cohort of patients. First,
the prevalence was high. Secondly, thrombocytopenia
was accompanied by pancytopenia in almost half (44%)
and complicated by bleeding in more than 1/10 (12%)
of the patients. Lastly, although the rate of patients with
AIDS diagnosis was different in patients with and without
thrombocytopenia (64.7% vs. 34.4%), a significantly lower
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Table 1. Characteristics of 95 HIV-infected patients.
Parameter

Results

Sex, % (n)
Male
Female

80.0 (76)
20.0 (19)

Median age at the time of diagnosis (range, years)

35 (1–216)

Median duration of follow-up (range, months)

50.9 (1–216)

Median duration of HIV infection (range, months)

38 (1–228)

New HIV diagnosis at first admission, n (%)

83.2 (79)

AIDS diagnosis, % (n)

45.3 (43)

Patients on cART, % (n)
Median duration of treatment (range, months)

72.6 (69)
34 (1–146)

Opportunistic infections, % (n)

14.7 (14)

Other infections, % (n)

61.1 (58)

Malignancy, % (n)

6.3 (6)

Exitus, % (n)

6.3 (6)

Table 2. Characteristics of 34 HIV-infected patients with thrombocytopenia.
Parameter

Results

Sex, % (n)
Male
Female

88.2 (30)
11.8 (4)

Median age at the time of diagnosis (range, years)

37 (16–71)

Thrombocytopenia at first admission, % (n)
Thrombocytopenia during follow-up
Thrombocytopenia while receiving cART

52.9 (18)
47.1 (16)
35.3 (12)

Isolated thrombocytopenia, % (n)
Thrombocytopenia and anemia
Thrombocytopenia and neutropenia
Pancytopenia

32.4 (11)
20.6 (7)
2.9 (1)
44.1 (15)

Platelet count, % (n)
101,000–150,000/µL
50,000–100,000/µL
<50,000/µL

32.4 (11)
38.2 (13)
29.4 (10)

Duration of thrombocytopenia, % (n)
<3 months
≥3 months

52.9 (18)
47.1 (16)

Bleeding, % (n)

11.8 (4)

Administration of fresh frozen plasma, % (n)

14.7 (5)

Exitus, (%) n

14.7 (5)
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Table 3. Comparison of patients with thrombocytopenia (cases) and without thrombocytopenia (controls) regarding continuous variables.
Parameter

Cases, n = 34

Controls, n = 61

P-value

Median age at the time of diagnosis (range, years)

37 (16–64)

38 (24–71)

>0.05

Median duration of follow-up (range, months)

44 (2–216)

33.5 (1–156)

>0.05

Median duration of HIV infection (range, months)

49 (3–218)

34 (1–228)

>0.05

Baseline median CD4+ T lymphocyte count (range, cells/µL)

159 (0–628)

367.5 (11–1380)

<0.05

Baseline median plasma HIV-RNA (range, copies/mL)

42,250
(<20–2,570,000)

40,050
(<20–5,730,000)

>0.05

Baseline median neutrophil count
(range, cells/µL)

3260
(385–7980)

3300
(1130–7230)

>0.05

Baseline mean white blood cell count (SD, cells/µL)

5400 (2800)

6300 (1900)

>0.05

Baseline median hemoglobin level (range, g/dL)

12.6 (6.38–17.4)

13.4 (4.5–16.7)

>0.05

Table 4. Comparison of patients with thrombocytopenia (cases) and without thrombocytopenia
(controls) regarding categorical variables.
Parameter

Cases (n = 34)
% (n)

Controls (n = 61)
% (n)

P-value

HBsAg positivity

2.9 (1)

6.5 (4)

> 0.05*

Anti-HCV positivity

14.7 (5)

0.0 (0)

<0.05*

Anti-Delta positivity

2.9 (1)

1.6 (1)

>0.05*

VDRL positivity

8.8 (3)

9.8 (6)

>0.05*

AIDS diagnosis

64.7 (22)

34.4 (21)

<0.05

cART usage

38.2 (13)

91.8 (56)

<0.05

Comorbid diseases

67.6 (23)

57.3 (35)

>0.05

Malignancy

8.8 (3)

4.9 (3)

>0.05*

Chemotherapy

5.8 (2)

1.6 (1)

>0.05*

CMV infection

14.7 (5)

3.2 (2)

>0.05*

TMP/SMX prophylaxis

50.0 (17)

29.5 (18)

<0.05

Azithromycin prophylaxis

41.7 (8)

3.2 (9)

>0.05

Fluconazole treatment

20.5 (7)

21.3 (13)

>0.05

Opportunistic infections

42.9 (6)

57.1 (8)

>0.05

Tuberculosis coinfection

17.6 (8)

7.8 (5)

<0.05*

Antituberculosis therapy

20.5 (7)

8.1 (5)

>0.05*

History of:

*Fisher’s exact test.

number of patients with thrombocytopenia were using or
ever had used cART.
Overall, the frequency of thrombocytopenia ranged
from 5% to 59% in HIV-infected patients. The rate
was higher in patients with AIDS (20% to 59%) than
patients without AIDS (5% to 15%) (22,29). Types of the
cytopenia may differ according to geographic regions. In
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a multicenter study, while anemia and neutropenia were
more frequent in South Africa, thrombocytopenia was
more frequent in Brazil and India (26). The definition of
thrombocytopenia differs among studies (18,29). In this
study, when all patients were included, the overall rates were
35.8%, 24.2%, and 10.5% for platelet count of <150,000/
µL, <100,000/µL, and <50,000/µL, respectively. These rates
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were higher than in earlier reports (19,30,31). Differences
among studies might be related to the differences in the
definition of thrombocytopenia or the heterogeneity of
the study population, or racial factors. In our study, low
median CD4+ T lymphocyte count at first admission (280
cells/µL), which is consistent with late diagnosis of HIV
infection, might be one explanation.
In a multicenter study, the frequency of
thrombocytopenia (<125,000/µL) in ART-naive patients
was 7.2% (26). In another study, however, even in the era
of cART, frequency of thrombocytopenia (platelet count
of <150,000/µL) ranged from 9.2% in patients without
AIDS to 21.2% in patients with AIDS (18). Similarly, in
our study, the frequency of thrombocytopenia was higher
in patients with AIDS (51.2%) than patients without AIDS
(23.1%).
Studies have shown that the frequency of
thrombocytopenia in HIV infection also differs according
to sex. The rate was higher in males than females (18,19,26).
Regarding age, however, there was no consistency among
studies (3,18,31–34). In our study, the 2 groups were
similar regarding sex and age.
Many studies showed that thrombocytopenia was
more frequent and more severe in patients who were in
more advanced stages of HIV infection, or who had lower
CD4+ T lymphocyte counts (3,6,18,22,25,31,32,35,36).
Regarding the relationship between thrombocytopenia
and plasma HIV-RNA levels, however, reports are not
consistent (6,25,31,36–38). Similar to these findings,
in our study, patients with thrombocytopenia had a
significantly lower median CD4+ T lymphocyte count
than the control group (P < 0.05), but the median plasma
HIV-RNA levels were similar between the 2 groups (P
> 0.05). Consequently, frequency of thrombocytopenia
was higher in patients who had used TMP/SMX for the
prophylaxis of opportunistic infections because of low
CD4+ T lymphocyte counts. Although TMP/SMX can
cause thrombocytopenia (20), in none of our patients its
use was the cause of thrombocytopenia.
The effect of cART on cytopenias was also evaluated in
earlier studies. Overall, the rate of thrombocytopenia was
9.8% in patients on cART for 96 weeks (36). Antiretroviral
therapy favorably affected all cytopenias, including
thrombocytopenia (37,39), whereas interruption of cART
was associated with emergence of thrombocytopenia in
several studies (36,40). In our study, similarly, the rate
of thrombocytopenia was significantly higher in cARTnaive patients than patients on cART. Although cART
favorably affected cytopenias, among antiretroviral drugs,
delavirdine, didanosine, indinavir, lamivudine, nelfinavir,
nevirapine, saquinavir, ritonavir, and zidovudine were
associated with thrombocytopenia (24,41). In one of our

patients, after all other causes were excluded, the cause of
thrombocytopenia was related to didanosine usage.
Although the frequency of thrombocytopenia
was associated with the CD4+ T lymphocyte count at
first admission, no relationship was found between
opportunistic infections in general and thrombocytopenia.
When the analysis was repeated specifically for
tuberculosis, however, the frequency of thrombocytopenia
was significantly higher in patients who either at present
or in the past had tuberculosis. Unlike other opportunistic
infections, tuberculosis, and especially pulmonary
involvement, can be seen in all stages of HIV infection, and
in most coinfected patients CD4+ T lymphocyte counts
were higher than 500 cells/µL (42). In our cohort, however,
coinfected patients with HIV and tuberculosis were in more
advanced stages of HIV infection with a median CD4+
T lymphocyte count of 73 cells/µL: (range: 1–686 cells/
µL), and this might be the explanation for the association
between tuberculosis and thrombocytopenia. Drugs
used for the treatment of tuberculosis, namely isoniazid,
rifampicin, rifabutin, ethambutol, and ethionamide, can
also cause thrombocytopenia (43–46), but in none of our
patients was the cause of thrombocytopenia related to
antituberculous drugs.
In our study, the frequency of thrombocytopenia
was significantly higher in HCV-coinfected patients, and
earlier studies also supported this finding (21,25,47).
Regarding HBV, however, only 1 study reported hepatitis
B surface antigen (HBsAg) positivity as a risk factor for
thrombocytopenia in HBV-coinfected patients (26). No
association was found in our study.
Reports of the effect of thrombocytopenia on
mortality rates in HIV-infected patients differ among
studies. Some studies reported higher rates of mortality
(3–5), and others did not find a relationship between
thrombocytopenia and prognosis of HIV infection (48–
50). In our study the mortality rate was higher in patients
with thrombocytopenia than without (14.7% vs 1.6%). It
was also noteworthy that 5 of the 6 deaths during the study
period were in thrombocytopenic patients.
The results of this study should be interpreted within
the context of its limitations. The main limitation was the
single-center, retrospective design of the study. The results
cannot be generalized to all HIV-infected patients. The
study power was low and type 2 error was high due to
the low sample size. Thus, some differences between the 2
groups might be missed. In addition, multivariate analysis
was not performed as the data set was not appropriate.
Despite these limitations, in our study, total follow-up
duration was 403 patient-years and the comparison of
the case and the control groups enabled us to derive
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more information than earlier reports of frequencies
of thrombocytopenia in different countries. Still, more
comprehensive studies are needed in this field.
In conclusion, we found thrombocytopenia in 34
(35.8%) patients. The main finding was the clear association

between thrombocytopenia and advanced (low CD4+ T
lymphocyte count, AIDS diagnosis, need for TMP/SMX
prophylaxis) and uncontrolled (antiretroviral-naive) HIV
infection. Tuberculosis and HCV coinfections were also
identified as associated factors for thrombocytopenia.
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